Australia markets open in 6 hours 32 minutes

Shanghai Junshi Biosciences Co., Ltd. (SHJBF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
11.450.00 (0.00%)
As of 12:36PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close11.45
Open11.45
BidN/A x N/A
AskN/A x N/A
Day's range11.45 - 11.45
52-week range11.45 - 11.45
Volume400
Avg. volume0
Market cap7.889B
Beta (5Y monthly)-0.03
PE ratio (TTM)N/A
EPS (TTM)-0.17
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Junshi Biosciences and Coherus Announce Toripalimab Granted Orphan Drug Designation in the United States for Esophageal Cancer

    SHANGHAI, China and REDWOOD CITY, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc. (“Coherus”, Nasdaq: CHRS) announced today that the United States Food and Drug Administration ("FDA") has granted Orphan Drug Designation (ODD) for toripalimab for the treatment of esophageal cancer. Orphan drug designation is granted to drugs and biologics intended to treat rare diseases with a patient pop

  • GlobeNewswire

    Coherus and Junshi Biosciences Announce Toripalimab Granted Orphan Drug Designation in the United States for Esophageal Cancer

    REDWOOD CITY, Calif. and SHANGHAI, China, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced today that the United States Food and Drug Administration ("FDA") has granted Orphan Drug Designation (ODD) for toripalimab for the treatment of esophageal cancer. Orphan drug designation is granted to drugs and biologics intended to treat rare diseases with a patient pop

  • GlobeNewswire

    TopAlliance Appoints Virginia Ellen Maher, MD, as Vice President of Medical Sciences

    SHANGHAI, China, Nov. 01, 2021 (GLOBE NEWSWIRE) -- TopAlliance Biosciences, a wholly own subsidiary of Junshi Biosciences (HKEX: 1877; SSE: 688180) today announced the appointment of Dr. Virginia Ellen Maher as VP of Medical Sciences, reporting to the company's Chief Medical Officer Dr. Patricia Keegan. In her new role, she will lead or support the company’s regulatory filing activities and assist Dr. Keegan in overseeing the company’s overall clinical development programs. Dr. Maher has 30 year